At a glance

ClinicalIndex Comparison Record

N/ACompleted· 816 enrolled

Drug / intervention

Efavirenz +1 moredrug

Likely dose

Efavirenz 600mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00120510

NCT00120510N/ACompleted

Compare CT.gov

A Randomized Clinical Trial to Determine the Efficacy of Early Versus Standard Antiretroviral Therapy in HIV Infected Adults With CD4+ T Cell Counts Between 200 and 350 Cells/mm3

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Jul 18, 2005·Updated Oct 15, 2014

In Brief

A clinical study evaluating Efavirenz and Lamivudine/Zidovudine for HIV Infections and Tuberculosis. Completed, enrolled 816 participants across 1 site.

Detailed Summary

Anti-HIV treatment consisting of lamivudine/zidovudine (3TC/ZDV) and efavirenz (EFV) is the current standard of care for initial treatment of HIV in most areas of the world. The purpose of this study is to determine the best time to start this anti-HIV treatment in treatment-naive adults in Haiti.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsHIV Infections, Tuberculosis

CountriesHaiti

Collaborators--

Timeline

N/ACompletedFinished

20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

First PostedJul 2005

Enrollment StartJul 2007

Primary CompletionSep 2009

TodayJul 2026

First PostedJul 18, 2005

Enrollment StartJul 1, 2007

Primary CompletionSep 1, 2009

TodayJul 2, 2026

Enrollment to primary: 2.2 yearsPosted 21.0 years ago

Interventions

Efavirenzdrug

Non-nucleoside reverse transcriptase inhibitor dosed at 600mg taken by mouth every 24 hours at bedtime

Lamivudine/Zidovudinedrug

Nucleoside reverse transcriptase inhibitor dosed at 150mg/300mg fixed dose combination taken by mouth every 12 hours